

## Erratum for Ikeda et al., “Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease”

Suguru Ikeda,\* Takaaki Sugihara,\* Yoshiki Hoshino,\* Yukako Matsuki,\* Takakazu Nagahara,\* Jun-ichi Okano,\* Sonoko Kitao,† Youhei Fujioka,† Kazuhiro Yamamoto† and Hajime Isomoto\*

*\*Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and †Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan*

### ERRATUM

Yonago Acta Med. 2020;63(3):188–197 doi: 10.33160/yam.2020.08.009

There was an error in the notation of the number of administrations. The notation should be corrected as follows:

On page 191, left column, line 25

Error: Three patients (17.6%) were given 0.1 mg bid (twice-daily), twelve (70.6%), 0.2 mg bid, and two (11.8%), 0.4 mg bid of pemafibrate, respectively.

Correction: Three patients (17.6%) were given 0.1 mg qd (once-daily), twelve (70.6%), 0.1 mg bid (twice-daily), and two (11.8%), 0.2 mg bid of pemafibrate, respectively

On page 191, right column, line 8

Error: Three biopsy-proven NASH patients were administered 0.2 mg bid of pemafibrate.

Correction: Three biopsy-proven NASH patients were administered 0.2 mg daily of pemafibrate.

On page 191, right column, line 39

Error: Fenofibrate administration needs to be at least 106.6 mg to 160 mg qd (once-daily); on the other hand, only 0.2 to 0.4 mg bid of pemafibrate is needed.

Correction: Fenofibrate administration needs to be at least 106.6 mg to 160 mg qd; on the other hand, only 0.2 to 0.4 mg daily of pemafibrate is needed.

On page 192, right column, line 2

Error: In phase 3, 58 (53.2%) subjects with fatty liver were administered 0.2 mg or 0.4 mg bid of pemafibrate;

Correction: In phase 3, 58 (53.2%) subjects with fatty liver were administered 0.2 mg or 0.4 mg daily of pemafibrate;

On page 195, right column, line 6

Error: Both were administered 0.2 mg bid.

Correction: Both were administered 0.2 mg daily.

The authors sincerely apologize for these errors and any confusion they may have caused.